In the NICE guidelines, an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) is recommended as first-line treatment among patients with hypertension and type 2 diabetes. This evidence concerns the gene ACE and hypertensive disorder.